QXQian Xu

Qian Xu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Qian Xu has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Dengping Li

    Department of CT Magnetic Resonance, Shouguang People's Hospital, Shouguang, Shandong 262700, P.R. China

    1 shared publication
  • Guanhua Li

    Department of Respiratory Medicine, Shouguang People's Hospital, Shouguang, Shandong 262700, P.R. China

    1 shared publication
  • Jinbing Xia

    Clinical Laboratory, Shouguang People's Hospital, Shouguang, Shandong 262700, P.R. China

    1 shared publication
  • Wenying Xia

    Clinical Laboratory, Shouguang Hospital of Traditional Chinese Medicine, Shouguang, Shandong 262700, P.R. China

    1 shared publication
  • Xiaoliang Zhu

    Department of Gastrointestinal Surgery, Yidu Central Hospital of Weifang, Qingzhou, Shandong 262500, P.R. China

    1 shared publication
  • Zhenyong Qi

    Clinical Laboratory, Shouguang People's Hospital, Shouguang, Shandong 262700, P.R. China

    1 shared publication

Latest Publications

  • Open Access

    Upregulated miR‑665 expression independently predicts poor prognosis of lung cancer and facilitates tumor cell proliferation, migration and invasion

    by Jinbing Xia, Dengping Li, Xiaoliang Zhu, Wenying Xia, Zhenyong Qi, Guanhua Li, Qian Xu

    Non-small cell lung cancer (NSCLC) is one of the leading causes of global cancer-associated mortality. Aberrant microRNAs (miRs) have been reported to be involved in the pathogenesis of various cancer types. The present study aimed to investigate the expression profile and prognostic value of miR‑665 in patients with NSCLC, and to analyze its functional role in tumor progression using NSCLC cells. Reverse transcription‑quantitative PCR was used to estimate the expression levels of miR‑665. Kaplan‑Meier survival curves and Cox regression analysis were performed to evaluate the prognostic value of miR‑665. The effects of miR‑665 on NSCLC cell proliferation, migration and invasion were examined by cell transfection, and the target gene of miR‑665 was explored. miR‑665 expression was elevated in the tissue and cell samples of NSCLC. This increased miR‑665 expression was associated with lymph node metastasis and TNM stage. An independent association between miR‑665 and overall survival was identified in patients with NSCLC. When regulating the expression levels of miR‑665 in vitro, NSCLC cell proliferation, migration and invasion were enhanced by overexpression of miR‑665, but were inhibited by knockdown of miR‑665. The luciferase activity results indicated that the protein tyrosine phosphatase receptor type B (PTPRB) was a direct target of miR‑665 in NSCLC cells. The present study provided evidence for the clinical significance of a decreased expression of miR‑665 in the prognosis of NSCLC. Upregulation of miR‑665 contributed to tumor cell proliferation, migration and invasion by targeting PTPRB, suggesting the potential of miR‑665 as a candidate therapeutic target for NSCLC treatment.